Akums Drugs and Pharmaceuticals Limited Share Price & Stock Analysis

Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS, BSE: 544222) is a Delhi-based company in the Domestic contract manufacturers industry. With a market capitalisation of ₹11,787 Cr, it ranks #547 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 4 in Domestic contract manufacturers. At ₹713.00 (as of 19 Nov 2026), the share price is 15.0% below its 52-week high of ₹838.80 and 74.2% above its 52-week low of ₹409.30. The share price is up 57.3% over one year and down 5.3% over three months.

Key Metrics

Current Price₹713.00
Market Cap₹11,787 Cr
NSE SymbolAKUMS
BSE Code544222
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services > Domestic contract manufacturers
P/E Ratio45
Return on Equity8.02%
Return on Assets4.84%
52-Week Range₹409.30 – ₹838.80
1-Year Price Change+57.3%
3-Month Price Change-5.3%
Beta (1Y)0.31
Dividend Yield0.13%
HeadquartersDelhi
Websitewww.akums.in

Latest Quarterly Results — Q2 FY27

Revenue₹1,342 Cr
Net Profit₹115 Cr
Net Margin8.5%
EPS (Basic)₹7.37
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Akums Drugs and Pharmaceuticals Limited Quarterly Revenue and Profit Trend

Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,342 Cr in Q2 FY27, up 31.9% from ₹1,018 Cr in Q2 FY26 and up 15.1% from ₹1,167 Cr in Q1 FY27. It posted a net profit of ₹115 Cr for the quarter, against a net profit of ₹43 Cr in Q2 FY26 (up 168.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,018 Cr (Q2 FY26) to ₹1,342 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹1,342 Cr₹115 Cr8.5%
Q1 FY27₹1,167 Cr₹101 Cr8.7%
Q4 FY26₹1,158 Cr₹81 Cr7.0%
Q3 FY26₹1,160 Cr₹68 Cr5.8%
Q2 FY26₹1,018 Cr₹43 Cr4.2%
Q1 FY26₹1,024 Cr₹65 Cr6.3%
Q4 FY25₹1,056 Cr₹150 Cr14.2%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 75.26% of Akums Drugs and Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 46.8% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).

About Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.

Products and Services

1. CDMO-This segment engages in the research and development, preparation and regulatory filing of dossiers; manufacturing formulations on contract basis and job work; and provides testing services. 2. API-This segment engages in the manufacture and sale of active pharmaceutical ingredient products. 3. Domestic Branded Formulations-This segment engages in the marketing of branded pharmaceutical formulations. 4. International Branded Formulations-This segment engages in the marketing of pharmaceutical formulations.

Business Segments

1. CDMO-85.1% 2. API-5.3% 3. Domestic Branded Formulations-10.2% 4. International Branded Formulations-3.3% 5. #PEND-2.3%

Akums Drugs and Pharmaceuticals Limited vs Peers — Domestic contract manufacturers

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Akums Drugs and Pharmaceuticals Limited₹11,787 Cr458.02%₹1,342 Cr+57.3%
INNOVA CAPTAB LIMITED₹6,249 Cr47.314.03%₹496 Cr+37.2%
Windlas Biotech Ltd₹2,060 Cr32.612.23%₹264 Cr+18.9%
Influx Healthtech Limited₹588 Cr28.720.39%——

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited is trading at ₹713.00, with a market capitalisation of ₹11,787 Cr.

Which sector does Akums Drugs and Pharmaceuticals Limited belong to?

Akums Drugs and Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Domestic contract manufacturers).

What are the key financial ratios of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited has a P/E of 45 and a return on equity of 8.02%.

What is the stock symbol of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited is listed on the NSE under the symbol AKUMS and on the BSE under the scrip code 544222.

How has Akums Drugs and Pharmaceuticals Limited's share price moved over the past year?

Akums Drugs and Pharmaceuticals Limited's share price is up 57.3% over one year and down 5.3% over three months. Its 52-week range is ₹409.30 to ₹838.80.

What were Akums Drugs and Pharmaceuticals Limited's latest quarterly results?

In Q2 FY27, Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,342 Cr and net profit of ₹115 Cr, with basic EPS of ₹7.37 (consolidated, parsed from the company's exchange filing).

How have Akums Drugs and Pharmaceuticals Limited's revenue and profit changed over the past year?

Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,342 Cr in Q2 FY27, up 31.9% from ₹1,018 Cr in Q2 FY26 and up 15.1% from ₹1,167 Cr in Q1 FY27.

What is the promoter holding in Akums Drugs and Pharmaceuticals Limited?

Promoters held 75.26% of Akums Drugs and Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 19 Nov 2026. Descriptive market data only — not investment advice.